Theranostics- the use of radiolabelled compounds for therapy and diagnosis 


Lecture Hall IX, University Main Building, Uppsala
Biskopsgatan 3
Uppsala, 75105 Sweden

Theranostics- the use of radiolabelled compounds for therapy and diagnosis 

April 12, 2024 @ 09:00 16:30 CEST

Welcome to a symposium arranged by the Drug Discovery and Development platform together with the Department of Immunology, Genetics and Pathology at Uppsala University and the Department of Oncology and Pathology at Karolinska Institutet. You can expect to learn and discuss different topics reaching from selecting a target for therapy, the research process to develop a candidate drug to the regulatory framework for theranostics.

Theranostics is a term used to describe when radioactive drugs are used as diagnostic and therapeutic pairs. Receptors that are overexpressed in the diseased tissue, e.g. tumors, are used to guide the drug to the target. The radiation can then either be used to for imaging or for therapy depending on the radionuclide used. Developing a theranostic agent could be a feasible way to reach the clinic and SciLifeLab is well suited to catalyze this process. We have gathered renowned speakers to discuss different aspects of the process from bench to bedside. We envision to inspire researcher with clinically relevant ideas to consider this relatively new technique as a feasible approach to reach the clinic. We also hope to gather researchers that are already in the field as well as infrastructure personnel.

Organizing committee: Marika Nestor, UU; Thuy Tran, KI; Jonas Rehn, Elekta; Ulrika Yngve, SciLifeLab DDD

Confirmed speakers

  • Theranostics and Radiomolecular Precision Oncology: Navigating the Past and Charting the Future of Nuclear Medicine  (Prof Dr Richard P Baum, CURANOSTICUM Wiesbaden-Frankfurt) 
  • Translating Innovation: Advancing Cancer Radiopharmaceutical 177Lu-AKIR001 to Clinical Trials (Professor Marika Nestor, UU) 
  • Why we need new targets for radiopharmaceutical therapy – and how to find them (Assistant Professor Kasper Karlsson, KI)  
  • Development of a Theranostic Product Pair for patients with HER2 Expressing Disease: An Industrial Perspectiv (Professor Fredrik Frejd, CSO, Affibody AB) 
  • Theranostics from a regulatory perspective (Dr Anna Sundlöf, Clinical Assessor, Swedish Medical Product Agency) 
  • Theranostic specific infrastructures for your research/project: from bench to bedside (Associate Professor Thuy Tran, KI and Associate Professor Renske Altena, KI)

Last updated: 2024-02-16

Content Responsible: Isolde Palombo(